Current news
Pharmatest at AACR Annual Meeting 2026
We are pleased to announce that Pharmatest Services will participate in the AACR Annual Meeting 2026, taking place in San
BIO-Europe Spring 2026
Pharmatest participated BIO‑EUROPE Spring in Lisbon, Portugal, March 23–25, 2026. The conference brought together the companies of the bio industry for
Conferences 2026
In 2026, our team will be on the road connecting with the global scientific community across oncology and musculoskeletal research.
Season’s greetings!
Happy holidays and season’s greetings! Pharmatest wants to thank all its clients and collaborators for the year 2025. We are
Pharmatest at ASH 2025
We’re excited to share that research supported by our preclinical team was featured at the ASH 2025 Annual Meeting, taking
Pharmatest at career events
Pharmatest has recently participated in two local career events: BioBridge: Career Fair and BION – Biomedical Industry Opportunities & Networking
New board member, Jenni Vuola
Jenni Vuola has started as a new board member of Pharmatest Services. She holds a PhD in microbiology and is
Women’s Health Hub Finland
We’re excited to be part of Women’s Health Hub Finland (WHHF), an initiative driving innovation in female-focused healthcare (https://businessturku.fi/en/womens-health-hub-finland/). As
Norwegian Conference for Hereditary Neuromuscular Disorders
We’re proud to share that Pharmatest will participate in the Norwegian Conference for Hereditary Neuromuscular Disorders 2025, a premier gathering
ASBMR 2025, Seattle, WA, USA
Pharmatest is proud to participate in the ASBMR Annual Meeting 2025 and the 2025 ASBMR/RBDA Symposium on Rare Bone Diseases: From
BIO International Convention, Boston, MA, USA
We are excited to announce our participation in the BIO International Convention, Boston, MA, USA, Boston Convention & Exhibition Center,
AACR 2025
AACR 2025 will be in Chicago this year and Pharmatest is participating, April 25-30! You can meat our team (Jukka
OARSI World Congress on Osteoarthritis 2025
Pharmatest will participate the OARSI 2025 World Congress on Osteoarthritis in South Korea, April 24-27! This congress is an annual
Conference participation in 2025
Pharmatest will have a busy conference season! You can meet us in the following occasions: OARSI 2025 World Congress on
Season’s greetings from Pharmatest
As we approach the end of another remarkable year, we want to take a moment to express our heartfelt gratitude
Pharmatest is among the TOP 60 companies chosen by Kasvu Open
Pharmatest chosen for the TOP 60 companies of Kasvu Open program Kasvu Open aims at supporting the selected companies in
Collaboration of the Nordic EUROSTARS Consortium Continues
The Fruitful Collaboration of the Nordic EUROSTARS Consortium Continues Pharmatest Services is proud to be a partner in the NK-ENGAGE
Pharmatest will participate in ASBMR Annual Meeting 2024
Pharmatest will participate in ASBMR Annual Meeting 2024 and Rare Bone Disease Symposium on Exploring and Expanding Treatments and Analytical
Pharmatest has successfully completed ISO 9001 audit
We are delighted to announce that Pharmatest has successfully renewed its ISO 9001 certification. ISO 9001 is an internationally recognized
Pharmatest was chosen for a growth program by Kasvu Open
Pharmatest chosen for the Kasvu Open program Kasvu Open aims at supporting the selected companies in their journey towards growth.
Pharmatest receives bronze medal from EcoVadis
Pharmatest obtained a bronze medal from EcoVadis assessment Sustainability is an essential factor for business nowadays. Pharmatest is aiming at
Pharmatest receives approval of the French Tax Credit Incentive (Crédit d’Impôt Recherche CIR)
Pharmatest has received the renewal of its French Tax Credit approval for the years 2024-2028. What is French Tax Credit?
Pharmatest will attend the AACR Annual Meeting 2024 in San Diego
We are happy to announce that we will participate the AACR Annual Meeting 2024! You are welcome to visit our
Pharmatest launches new research model for osteoarthritis: Mouse DMM model
The destabilization of the medial meniscus (DMM) mouse model is a widely used surgical model in osteoarthritis research to study
Nordic Consortium Advancing Immunotherapy for Multiple Myeloma in a EUROSTARS funded program
Pharmatest Services is part of the NK-ENGAGE project (Novel Synthetic Polypeptides for Natural Killer Cell -mediated Immunotherapy for the Treatment
Pharmatest to participate in the ASBMR 2023 in Vancouver
We are delighted to announce our participation in ASBMR 2023 Annual Meeting. The meeting will take place in Vancouver, Canada
New publication assessing bone health effects of radium-223 combo treatment in prostate cancer bone metastases model
New study assessing bone health effects of radium-223, abiraterone acetate, prednisone, and zoledronic acid combo treatment in prostate cancer bone
Celebrating 25 Years of Excellence
Pharmatest Services’ Journey of Advancing Drug Discovery Pharmatest is thrilled to mark a significant milestone in our journey – our
Pharmatest to exhibit and present at the AACR 2023 Annual Meeting
We will be presenting three abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2023 held in Orlando April
Exciting results in new study on bone-metastatic castration-resistant prostate cancer
Proud to present the results of our latest collaboration with Bayer AG and Aurexel Life Sciences! Our newest article, published
October – breast cancer awareness month
Breast cancer is the most common cancer globally, according to the World Health Organization. It accounts for 12% of all
Pharmatest to present at ASBMR 2022 Annual Meeting
The American Society for Bone and Mineral Research (ASBMR) is a professional, scientific, and medical society with approximately 4,000 members
Pharmatest announces its attendance at the AACR 2022. Visit our booth #1465!
Pharmatest is excited to join the meeting onsite from April 8 through 13, 2022 at the Ernest N. Morial Convention
Holiday Greetings
As 2021 is coming to an end, we would like to thank all of our customers, partners and employees for
Breast Cancer Awareness Month
Early detection saves lives October is Breast Cancer Awareness month. It is an important cause to raise awareness and understanding
Proud to announce ISO 9001:2015 certification
We are delighted to announce that Pharmatest is now an ISO 9001:2015 certified company. This is an internationally recognized standard
Promising therapy for multiple myeloma bone disease has been published
Myeloma bone disease is still incurable and is characterized by destructive osteolytic lesions causing bone pain, fractures, and hypercalcemia. Our
Pharmatest receives the French Tax Credit Incentive (Crédit d’Impôt Recherche CIR)
Pharmatest has received the renewal of its French Tax Credit approval for the years 2021, 2022, 2023. The French Tax
Attending the largest annual cancer research meeting AACR
Along with 11,000 other participants, Pharmatest will be taking part of the virtual AACR 2021 Meeting starting on April 10.
LIVE Webinar: To Overcome the Challenges in Cancer Treatment – From Bone Metastasis to Nanotechnology
Pharmatest would like to invite you to the live Webinar on Tuesday 4th May at 4 pm BST (6 pm
NEW LEAD MOLECULE FOR NOVEL ANTI-OSTEOPOROTIC DRUG PUBLISHED
A new lead molecule (compound E197) for novel anti-osteoporotic drug has been identified at the Montpellier Cell Biology Research Center
PHARMATEST TO ATTEND 3RD ANNUAL ADVANCES IN IMMUNO-ONCOLOGY US CONGRESS
This week on Thursday October 15th our oncology experts will virtually travel and attend the 3rd Annual Advances in Immuno-Oncology
ASBMR 2020 VIRTUAL ANNUAL MEETING
Pharmatest will be taking part of the virtual ASBMR 2020 Meeting starting on Friday, September 11. We are excited about this year’s
PHARMATEST AT AACR 2020 VIRTUAL MEETING
PHARMATEST AT AACR 2020 VIRTUAL MEETINGPharmatest is very excited to participate in AACR virtual meeting II on June 22-24. Registration
SUPPORTING THE RESEARCH RELATED TO COVID-19
In severe cases of SARS-CoV-2 infections, the immune system has been hyper-activated, triggering a cytokine release storm (CRS). CRS is
PHARMATEST’S PROJECTS AND SAFETY DURING THE COVID-19 OUTBREAK
Pharmatest’s projects and safety during the COVID-19 outbreak To ensure the health and safety of Pharmatest’s employees, we have adopted
